Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients

Gautret et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106236
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Report on the safety of HCQ+AZ with 3,737 COVID-19 patients. 138 had contraindications and treatment was discontinued in 12 cases due to QTc prolongation. There were no cases of torsade de pointe or sudden death.
Gautret et al., 4 Jan 2021, peer-reviewed, 4 authors.
This PaperHCQAll
Abstract: International Journal of Antimicrobial Agents 57 (2021) 106236 Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: www.elsevier.com/locate/ijantimicag Letter to the Editor Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients ✩ Declaration of Competing Interest The authors declare no competing interests. We agree with colleagues that the hydroxychloroquineazythromycin (HCQ-AZ) combination may potentially lead to drugdrug interactions [1]. Given that both drugs are known to have potential cardiotoxicity, we paid a rigorous attention to avoiding HCQ-AZ in patients with cardiac diseases, abnormal EKG, dyskalemia or the routine use of other interacting medications. The systematic pre-therapy workup included serum electrolyte analysis, and an electrocardiogram with corrected QT measurement (Bazett’s formula). Close serum electrolyte analysis monitoring was performed in patients with low serum potassium levels at baseline. An electrocardiogram was routinely performed 48 hours after the start of treatment. Treatment with HCQ was discontinued when the corrected QT interval (QTc, Bazett’s formula) was>500ms and the risk-benefit ratio of HCQ+AZ treatment was estimated by the infectious disease specialist and agreed with the cardiologist, to be between 460 and 500ms. The indications for this control ECG were restricted after an initial workup in 848 ECG from 424 patients (at day 0 and day 2 for each patient), showing that all contraindicative repolarization abnormalities had been detected on the first ECG [2]. Among 3,737 COVID-19 patients diagnosed at our institute in March-April 2020, 88 (2.4%) had cardiac contraindications to combination therapy, 45 (1.2%) patients were taking a drug with a potential risk of interactions with combination therapy and 10 (0.3%) had hypo or hyperkalaemia [3]. A total of 3,119 patients received HCQ-AZ for at least three days. QTc prolongation (>60 ms) was observed in 25 patients (0.67%), resulting in discontinuation of treatment in 12 cases, including three cases with QTc> 500 ms. No cases of torsade de pointe or sudden death were observed, including in the 9.5% of patients over 65 years of age. Our current observations and practices illustrate the efficacy of this risk management procedures associated with the prescription of HCQ-AZ, which presents an excellent safety profile in COVID-19 patients, including elderly patients [4]. We agree that doxycycline has shown in vitro effect on SARSCoV-2 [5]. However, synergistic between doxycycline and hydroxychloroquine in vitro effect has not been investigated so far, unlike azithromycin. Therefore, the combination of HCQ and doxycycline should only be proposed for patients with a contraindication to the HCQ-AZ regimen, independently of age. Funding No funding sources. Ethical approval Not applicable. References [1] Malek AE, Granwehr BP. Doxycycline as an alternative to azithromycin in elderly patients. Int J Antimicrob Agents. 2021:106168. [2] Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. May-Jun 2020;35:101738. [3] Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit